Analysis of outcomes in patients with ST-segment elevation myocardial infarction aged 90 years and older: a single center experience

Aim. To evaluate the effectiveness and safety of an invasive approach in patients with ST-segment elevation myocardial infarction (STEMI) aged 90 years and older.

Material and methods. This retrospective single-center study was conducted at the V. P. Polyakov Samara Regional Clinical Cardiology Dispensary. In 20132020, 104 patients aged 90 years and older were hospitalized with a diagnosis of STEMI. The mean age of patients was 91,7 years (90-100), while the proportion of women was 67,3%. Patients included in the analysis were divided into groups of conservative treatment (n=81, mean age, 91,9 (90-100) years, women 70,4%) and invasive management (coronary angiography + percutaneous coronary intervention (PCI)) (n=23, mean age, 91,0 (90-94) years, women, 56,5%).

Results. The groups were comparable in basic characteristics. In-hospital mortality in the conservative strategy group was 48,1% vs 17,4% in the invasive management group (p=0,009; odds ratio (OR) 3,35; 95% confidence interval (CI) 1,23-9,15). During the first year after discharge, 25,9% (n=21) died in the conservative strategy group and 30,4% (n=7) in the invasive strategy group (p=0,79; OR 0,85; 95% CI 0,42-1,75). In total (during the hospitalization period and within 1 year after discharge), 60 people (74,1%) died in the conservative strategy group, while in the invasive treatment group — 11 (47,8%) (p=0,02; OR 3,11; 95% CI 1,19-8,11). Life expectancy in patients with STEMI aged 90 years and older after discharge from hospital was 83,95 days for the conservative strategy group and 103,85 days for the invasive strategy group (p=0,67).

Conclusion. The data obtained in our study support primary PCI as a treatment strategy for patients with STEMI aged 90 years and older.

1. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023;ehad191. doi:10.1093/eurheartj/ehad191.

2. Arisha MJ, Ibrahim DA, Abouarab AA, et al. Percutaneous coronary intervention in the elderly: current updates and trends. Vessel Plus 2018;2:14. doi:10.20517/2574-1209.2018.29.

3. Pocock SJ, Ariti CA, Collier TJ, et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33(2):176-82. doi:10.1093/eurheartj/ehr352.

4. Duplyakova PD, Pavlova TV, Khokhlunov SM, et al. The management of patients aged 90 years and older with ST-segment elevation myocardial infarction. Science and Innovations in Medicine. 2023;8(1):29-33. (In Russ.) doi:10.35693/2500-1388-2023-8-1-29-33.

5. Russian Society of Cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/1560-40712020-4103.

6. Schoenenberger AW, Radovanovic D, Windecker S, et al. AMIS Plus Investigators. Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. Eur Heart J. 2016;37(16):1304-11. doi:10.1093/eurheartj/ehv698.

7. Phan DQ, Rostomian AH, Schweis F, et al. Revascularization Versus Medical Therapy in Patients Aged 80 Years and Older with Acute Myocardial Infarction. J Am Geriatr Soc. 2020;68(11):2525-33. doi:10.1111/jgs.16747.

8. Petroni T, Zaman A, Georges JL, et al. Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. Heart. 2016;102(20):1648-54. doi:10.1136/heartjnl-2015-308905.

9. Bueno H, Betriu A, Heras M, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardioeNAncianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011;32:51-60. doi:10.1093/eurheartj/ehq375.